Surgical treatment of hepatocellular carcinoma: Expert consensus statement

HPB

Volumn 12, Issue 5, 2010, Pages 302-310

  Jarnagin, William ^a   Chapman, William C ^b   Curley, Steven ^c   D'Angelica, Michael ^a   Rosen, Charles ^d   Dixon, Elijah ^e   Nagorney, David ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Ablation; Chemoembolization; Chemotherapy; Consensus conference; Hepatocellular cancer; Hepatoma; Laparoscopic; Laparoscopy; Liver transplantation; Radiotherapy; Surgery

Indexed keywords

THYMOSIN ALPHA1;

ABLATION THERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFERENCE PAPER; ELECTROPORATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LAPAROSCOPIC SURGERY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER PARENCHYMA; LIVER RESECTION; LIVER TRANSPLANTATION; MICROWAVE THERAPY; MORBIDITY; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; RADIOFREQUENCY ABLATION;

EID: 77953556964     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00182.x     Document Type: Conference Paper

References (70)

1. Parkin DM, Bray F, Ferlay J, Pisani P. (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156.
2. Bosch FX, Ribes J, Diaz M, Cleries R. (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5-S16.
3. El-Serag HB, Mason AC. (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750.
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430.
5. Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J et al. (2003) Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 238:711-719.
6. Infante-Rivard C, Esnaola S, Villeneuve JP. (1987) Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 7:660-664.
7. Bruix J, Sherman M. (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236.
8. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242:158-171.
9. Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K et al. (2005) Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234:954-960.
10. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al. (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47:82-89.
11. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al. (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321-328.
12. Heckman JT, Devera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE et al. (2008) Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 15:3169-3177.
13. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF et al. (2006) Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 12:665-673.
14. Serrano M, Neves A, Soares CM, Moran CP, Jr., Henriques AO. (2004) Role of the anti-sigma factor SpoIIAB in regulation of sigmaG during Bacillus subtilis sporulation. J Bacteriol 186:4000-4013.
15. Curley SA, Cherukuri P, Briggs K, Patra CR, Upton M, Dolson E et al. (2008) Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol 7:313-326.
16. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, Curley SA. (2008) Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology 6:2.
17. Gannon CJ, Cherukuri P, Yakobson BI, Cognet L, Kanzius JS, Kittrell C et al. (2007) Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 110:2654-2665.
18. Wei AC, Tung-Ping Poon R, Fan ST, Wong J. (2003) Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 90:33-41.
19. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al. (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229:322-330.
20. Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. (2008) Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am 17:607-633.
21. Fan STLC, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 229:322-330.
22. Man K, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. (1997) Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg 226:704-711.
23. Song TJ, Ip EW, Fong Y. (2004) Hepatocellular carcinoma: current surgical management. Gastroenterology 127:S248-260.
24. Belghiti J, Kianmanesh R. (2005) Surgical treatment of hepatocellular carcinoma. HPB (Oxford) 7:42-49.
25. Poon RT, Fan ST, Ng IO, Wong J. (2000) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231:544-551.
26. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ et al. (2007) Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 245: 36-43.
27. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J et al. (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364-373.
28. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J et al. (2005) Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 137:403-410.
29. Liau KH, Ruo L, Shia J, Padela A, Gonen M, Jarnagin WR et al. (2005) Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 104:1948-1955.
30. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. (2009) Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 249:118-123.
31. Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH et al. (2003) Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 238:315-321.
32. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235:373-382.
33. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F et al. (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238:885-892.
34. Vigano L, Tayar C, Laurent A, Cherqui D. (2009) Laparoscopic liver resection: a systematic review. J Hepatobiliary Pancreat Surg 16:410-421.
35. Buell JF, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I et al. (2009) The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg 250:825-830.
36. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699.
37. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M et al. (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533-539.
38. Marsh JW, Dvorchik I. (2003) Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl 9:693-696.
39. American Liver Tumor Study Group. A randomized prospective multiinstitutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. In: Investigators Booklet and Protocol. Richmond, Va: United Network for Organ Sharing; 1998.
40. Roayaie K, Feng S. (2007) Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl 13:S36-43.
41. Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH et al. (2006) Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 6:1957-1962.
42. Wiesner RH, Sorrell M, Villamil F. (2003) Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 9:S1-9.
43. Yao FY. (2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8:1982-1989.
44. Goodman J, Glasgow SC, Schnitzler M, Lowell JA, Shenoy S, Jendrisak MD et al. (2005) Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease. Arch Surg 140:459-464.
45. Jonas S, Al-Abadi H, Benckert C, Thelen A, Hippler-Benscheid M, Saribeyoglu K et al. (2009) Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 250:1008-1013.
46. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. (2002) Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8:765-774.
47. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V et al. (2002) Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8:873-883.
48. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403.
49. Schwartz M, Roayaie S, Uva P. (2007) Treatment of HCC in patients awaiting liver transplantation. Am J Transplant 7:1875-1881.
50. Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S et al. (2006) Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 203:411-420.
51. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD et al. (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248:617-625.
52. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K et al. (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238: 508-518.
53. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso M, Sala M et al. (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62-67.
54. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739.
55. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171.
56. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK et al. (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10:449-455.
57. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W et al. (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557-563.
58. Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T. (2009) A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl) 18:492-499.
59. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25.
60. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47-54.
61. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. (2009) A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int e-pub.
62. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R et al. (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240:900-909.
63. Murakami T, Ishimaru H, Sakamoto I, Uetani M, Matsuoka Y, Daikoku M et al. (2007) Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 30:696-704.
64. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252:905-913.
65. Mahnken AH, Bruners P, Gunther RW. (2009) Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Dig Dis 27:148-156.
66. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. (2009) Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 9:31.
67. Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M et al. (2005) Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9:1207-1215.
68. Llovet JM, Fuster J, Bruix J. (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434-1440.
69. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E et al. (2002) Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50:123-128.
70. Yao FY, Hirose R, LaBerge JM, Davern TJ, 3rd, Bass NM, Kerlan RK, Jr. et al. (2005) A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11:1505-1514.